Substance-induced psychosis and schizophrenia: the interaction point

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

One of the most severe complications of narcotic drugs misuse are induced psychotic disorders. Their frequency is varies from 5.2 to 100% and depends on the type of drug. This review provides current data and discussion on the similarities and differences between induced psychosis and schizophrenia. Possible interaction of pathogenic pathways, the possibility of differentiation at the clinical level and the main difficulties in clear diagnostic are discussed. The problem of transformation of induced psychoses into schizophrenia and the significance of differentiated treatment are also considered.

About the authors

Ilya А. Fedotov

Ryazan State Medical University

Author for correspondence.
Email: ilyafdtv@yandex.ru
ORCID iD: 0000-0002-2791-7180
ResearcherId: N-9456-2016

МD, PhD, Associate Professor of the Department of Psychiatry

Russian Federation, Ryazan

Diego Quattrone

Social, Genetic and Developmental Psychiatry Centre, Institute of Psychiatry, Psychology and Neuroscience, King’s College London

Email: ilyafdtv@yandex.ru
ORCID iD: 0000-0002-6051-8309
ResearcherId: I-2362-2019

Researcher in MRC Social, Genetic and Developmental Psychiatry Centre

United Kingdom, London

Dmitri I. Shustov

Ryazan State Medical University

Email: ilyafdtv@yandex.ru
ORCID iD: 0000-0001-7803-3388
SPIN-code: 3887-5475
ResearcherId: AAG-2198-2019

МD, PhD, Professor, Head of the Department of Psychiatry

Russian Federation, Ryazan

References

  1. World Drug Report 2020 (United Nations publication, Sales №E.20.XI.6). Available at: https://wdr. unodc.org/wdr2020/field/WDR20_BOOKLET_6.pdf Accessed: 2020 July 02.
  2. European Drug Report 2020: Trends and Developments. Luxembourg: Publications Office of the European Union; 2020.
  3. Koshkina EA, Val’kova UV, Smirnovskaya MS. Sovremennyye trendy razvitiya narkologicheskoy situatsii. In: Psikhicheskoye zdorov’ye cheloveka i obshchestva. Aktual’nyye mezhdistsiplinarnyye problemy; 30 Oct 2017; Moscow. Moscow; 2018. (In Russ).
  4. Li EA, Koren SV. COVID-19 pandemic and drug users. Journal of Addiction Problems. 2020;(6):72-83. (In Russ).
  5. Vallersnes OM, Dines AM, Wood DM, et al. Psychosis associated with acute recreational drug toxicity: a European case series. BMC Psychiatry. 2016;16:293. doi: 10.1186/s12888-016-1002-7
  6. Smith MJ, Thirthalli J, Abdallah AB, et al. Prevalence of psychotic symptoms in substance users:
  7. a comparison across substances. Comprehensive Psychiatry. 2009;50(3):245-50. doi: 10.1016/j.comp psych.2008.07.009
  8. Lecomte T, Dumais A, Dugré JR, et al. The prevalence of substance-induced psychotic disorder in methamphetamine misusers: A meta-analysis. Psychiatry Research. 2018;268:189-92. doi: 10.1016/j.psychres.2018.05.033
  9. Hobbs M, Kalk NJ, Morrison PD, et al. Spicing it up - synthetic cannabinoid receptor agonists and psychosis - a systematic review. European Neuro-psychopharmacology. 2018;28(12):1289-304. doi:10. 1016/j.euroneuro.2018.10.004
  10. Ragazzi TCC, Shuhama R, Menezes PR, et al. Cannabis use as a risk factor for psychotic-like experiences: A systematic review of non-clinical populations evaluated with the Community Assessment of Psychic Experiences. Early Intervention in Psychiatry. 2018;12(6):1013-23. doi: 10.1111/eip.12693
  11. Roncero C, Abad AC, Padilla-Mata A, et al. Psychotic Symptoms Associated with the use of Dopaminergic Drugs, in Patients with Cocaine Dependence or Abuse. Current Neuropharmacology. 2017;15(2):315-23. doi: 10.2174/1570159X14 6661 60324144912
  12. Tatetsu S, Goto A, Fujiwara T. Psychostimulant toxicosis. Tokyo: Igakushoin; 1956.
  13. Murray RM, Paparelli A, Morrison PD, et al. What can we learn about schizophrenia from studying the human model, drug-induced psychosis? American Journal of Medical Genetics. Part B: Neuro-psychiatric Genetics. 2013;162(7):661-70. doi:10.1002/ ajmg.b.32177
  14. Ghose S. Substance-Induced Psychosis: An Indicator of Development of Primary Psychosis? The American Journal of Psychiatry. 2018;175(4):303-4. doi: 10.1176/appi.ajp.2018.17121395
  15. Mendelevich VD. Psychotic disorders due to drug use: current state of the problem. Narcology. 2014; 13(7):93-100. (In Russ).
  16. Logutenko RM. Heteroaggressive and suicidal behavior of patients with paranoid schizophrenia with delusions of obsession. Nauka Molodykh (Eruditio Juvenium). 2015;(4):104-10. (In Russ).
  17. Fiorentini A, Volonteri LS, Dragogna F, et al. Substance-Induced Psychoses: A Critical Review of the Literature. Current Drug Abuse Reviews. 2011;4 (4):228-40. doi: 10.2174/1874473711104040228
  18. Howes OD, Kambeitz J, Kim E, et al. The nature of dopamine dysfunction in schizophrenia and what this means for treatment. Archives of General Psychiatry. 2012;69(8):776-86. doi: 10.1001/archgen psychiatry.2012.169
  19. Kegeles LS, Abi-Dargham A, Zea‐Ponce Y, et al. Modulation of amphetamine-induced striatal dopamine release by ketamine in humans: implications for schizophrenia. Biological Psychiatry. 2000;48 (7):627-40. doi: 10.1016/S0006-3223(00)00976-8
  20. McCutcheon RA, Krystal JH, Howes OD. Dopamine and glutamate in schizophrenia: biology, symptoms and treatment. World Psychiatry. 2020; 19(1):15-33. doi: 10.1002/wps.20693
  21. Ham S, Kim TK, Chung S, et al. Drug Abuse and Psychosis: New Insights into Drug-induced Psychosis. Experimental Neurobiology. 2017;26(1):11-24. doi: 10.5607/en.2017.26.1.11
  22. Khokhar JY, Todd TP. Behavioral predictors of alcohol drinking in a neurodevelopmental rat
  23. model of schizophrenia and co-occurring alcohol use disorder. Schizophrenia Research. 2018;194: 91-7. doi: 10.1016/j.schres.2017.02.029
  24. Brunette MF, Mueser KT, Babbin S, et al.
  25. Demographic and clinical correlates of substance use disorders in first episode psychosis. Schizophrenia Research. 2018;194:4-12. doi:10.1016/j. schres.2017.06.039
  26. Martinotti G., De Risio L., Vannini C., et al. Substance-related exogenous psychosis: a postmodern syndrome. CNS Spectrums. 2020;1-8. doi: 10.1017/S1092852920001479
  27. Caton CLM, Drake RE, Hasin DS, et al. Differences Between Early-Phase Primary Psychotic Disorders With Concurrent Substance Use and Substance-Induced Psychoses. Archives of General Psychiatry. 2005;62(2):137-45. doi: 10.1001/archpsyc.62.2.137
  28. Caton CLM, Hasin DS, Shrout PE, et al. Stability of early-phase primary psychotic disorders with con-current substance use and substance-induced psychosis. The British Journal of Psychiatry. 2007; 190(2):105-11. doi: 10.1192/bjp.bp.105.015784
  29. Mauri M, Di Pace C, Reggiori A, et al. Primary psychosis with comorbid drug abuse and drug-induced psychosis: Diagnostic and clinical evolution at follow up. Asian Journal of Psychiatry. 2017; 29:117-22. doi: 10.1016/j.ajp.2017.04.014
  30. Weibell MA, Joa I, Bramness J, et al. Treated incidence and baseline characteristics of substance induced psychosis in a Norwegian catchment area. BMC Psychiatry. 2013;13:319. doi: 10.1186/1471-244X-13-319
  31. Crebbin K, Mitford E, Paxton R, et al. First episode drug-induced psychosis: a medium term follow up study reveals a high risk group. Social Psychiatry and Psychiatric Epidemiology. 2009;44(9):710-5. doi: 10.1007/s00127-008-0490-2
  32. Fraser S, Hides L, Philips L, et al. Differentiating first episode substance induced and primary psy-chotic disorders with concurrent substance use in young people. Schizophrenia Research. 2012;136(1-3): 110-5. doi: 10.1016/j.schres.2012.01.022
  33. Piataeva IV, Kutashov VA, Khabarova TY. Differential diagnosis of endogenous and substance-induced (salt) psychosis. Central Science Bulletin. 2016;1(16):30-2. (In Russ).
  34. Dubatova I, Stojakin I, Karnauh K, et al. The analysis of clinical manifestations and peculiarities of psychotic disorders therapy in consumers of designer drugs. Glavnyy Vrach Yuga Rossii. 2018;(1): 52-6. (In Russ).
  35. Quattrone D., Ferraro L., Tripoli G., et al. Daily use of high-potency cannabis is associated with more positive symptoms in first-episode psychosis patients: the EU-GEI case – control study. Psychological Medicine. 2020;1-9. doi: 10.1017/S0033291720000082
  36. Martinotti G, Di Nicola M, Quattrone D, et al. Novel psychoactive substances and induced phenomena in psychopathology: the lysergic psychoma. Journal of Psychopathology. 2015;21: 400-5.
  37. Murray RM, Quattrone D, Natesan S, et al. Should psychiatrists be more cautious about the long-term prophylactic use of antipsychotics? The British Journal of Psychiatry. 2016;209(5):361-5. doi: 10.1192/bjp.bp.116.182683
  38. Halpern JH, Lerner AG, Passie T. A Review of Hallucinogen Persisting Perception Disorder (HPPD) and an Exploratory Study of Subjects Claiming Symptoms of HPPD. Current Topics in Behavioral Neurosciences. 2018;36:333-60. doi: 10.1007/7854_2016_457
  39. Litjens RPW, Brunt TM, Alderliefste G-J, et al. Hallucinogen persisting perception disorder and the serotonergic system: A comprehensive review including new MDMA-related clinical cases. European Neuropsychopharmacology. 2014;24(8):1309-23. doi: 10.1016/j.euroneuro.2014.05.008
  40. Lev-Ran S, Feingold D, Rudinski D, et al. Schizophrenia and hallucinogen persisting perception disorder: A clinical investigation: Schizophrenia and HPDD: Clinical Characteristics. The American Journal on Addictions. 2015;24(3):197-9. doi: 10.1111/ajad.12204
  41. Starzer MSK, Nordentoft M, Hjorthøj P. Rates and Predictors of Conversion to Schizophrenia or Bipolar Disorder Following Substance-Induced Psychosis. The American Journal of Psychiatry. 2018; 175 (4):343-50. doi: 10.1176/appi.ajp.2017.17020223
  42. Kendler KS, Ohlsson H, Sundquist J, et al. Prediction of Onset of Substance-Induced Psychotic
  43. Disorder and Its Progression to Schizophrenia in a Swedish National Sample. The American Journal of Psychiatry. 2019;176(9):711-9. doi: 10.1176/appi.ajp.2019.18101217
  44. Niemi-Pynttäri JA, Sund R, Putkonen H, et al. Sub-stance-Induced Psychoses Converting Into Schizophrenia: A Register-Based Study of 18,478 Finnish Inpatient Cases. The Journal of Clinical Psychia-try. 2013;74(1):e94-9. doi: 10.4088/JCP.12m07822
  45. Hjorthøj P, Starzer MSK, Benros ME, et al. Infections as a Risk Factor for and Prognostic Factor After Substance-Induced Psychoses. American Journal of Psychiatry. 2020;177(4):335-41. doi: 10.1176/appi.ajp.2019.19101047
  46. Murrie B, Lappin J, Large M, et al. Transition of Substance-Induced, Brief, and Atypical Psychoses to Schizophrenia: A Systematic Review and Meta-analysis. Schizophrenia Bulletin. 2020;46(3):505-16. doi: 10.1093/schbul/sbz102
  47. Gorelick DA. Pharmacological Treatment of Cannabis-Related Disorders: A Narrative Review. Current Pharmaceutical Design. 2016;22(42):6409-19. doi: 10.2174/1381612822666160822150822
  48. Sulaiman AH, Gill JS, Said MA, et al. A randomized, placebo-controlled trial of aripiprazole for the treatment of methamphetamine dependence and associated psychosis. International Journal of Psychiatry in Clinical Practice. 2013;17(2):131-8. doi: 10.3109/13651501.2012.667116
  49. Kekelidze ZI, Klimenko TV, Kozlov AA, et al. Differential approaches to the treatment of acute psychosis due to the use of synthetic cannabinoids. Zhurnal Nevrologii i Psikhiatrii im. S.S. Korsakova. 2017; 117(12):21. doi: 10.17116/jnevro201711712121-26
  50. Murray RM, Quigley H, Quattrone D, et al. Traditional marijuana, high-potency cannabis and synthetic cannabinoids: increasing risk for psychosis. World Psychiatry. 2016;15(3):195-204. doi: 10.1002/wps.20341
  51. Schoeler T., Monk A., Sami M.B., et al. Continued versus discontinued cannabis use in patients with psychosis: a systematic review and meta-analysis. The Lancet. Psychiatry. 2016;3(3):215-25. doi: 10.1016/S2215-0366(15)00363-6

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2021 Eco-Vector


 


Согласие на обработку персональных данных

 

Используя сайт https://journals.rcsi.science, я (далее – «Пользователь» или «Субъект персональных данных») даю согласие на обработку персональных данных на этом сайте (текст Согласия) и на обработку персональных данных с помощью сервиса «Яндекс.Метрика» (текст Согласия).